Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP131319.RAQMpOSG1sTqIVc9GPmBPwH3rRGxnNHEVN4Hp_8WbrJbI130_assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131319.RAQMpOSG1sTqIVc9GPmBPwH3rRGxnNHEVN4Hp_8WbrJbI130_provenance.
• NP131323.RAZdQ0rLqrKdN0smVmQD8SsAU-dDv6t5_6M-3O7TJ6FMw130_assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131323.RAZdQ0rLqrKdN0smVmQD8SsAU-dDv6t5_6M-3O7TJ6FMw130_provenance.
• assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP187023.RAXBCpZqQhHIZauJ9SD_-jUlwhi3BpXCWkBrus5IasNT8130_assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP187023.RAXBCpZqQhHIZauJ9SD_-jUlwhi3BpXCWkBrus5IasNT8130_provenance.
• NP187025.RAAyd5exPuxuTKNAHjCVFGiej-yv5kOe4yLK5r6_FVHBk130_assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP187025.RAAyd5exPuxuTKNAHjCVFGiej-yv5kOe4yLK5r6_FVHBk130_provenance.
• NP131317.RA4-TfNJieywYrXHsotK578cGRItdryc5SJ5Yt6PpBCg8130_assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131317.RA4-TfNJieywYrXHsotK578cGRItdryc5SJ5Yt6PpBCg8130_provenance.
• NP131321.RA6HBhHPp-KtecdOhm54IUv3hMPV0tuc57mZ17iy9tLso130_assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131321.RA6HBhHPp-KtecdOhm54IUv3hMPV0tuc57mZ17iy9tLso130_provenance.
• NP187024.RAIwnTU1_QjP8XG6ieN2HSuqh6WPippwF2r7p9CPNKBpA130_assertion description "[Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for developing febrile neutropenia. If confirmed, these preliminary findings may contribute to more individualized approaches of irinotecan treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP187024.RAIwnTU1_QjP8XG6ieN2HSuqh6WPippwF2r7p9CPNKBpA130_provenance.